世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

体外肺モデルの市場規模、シェア、動向分析レポート:タイプ別(2Dモデル、3Dモデル)、用途別(生理学研究、3Dモデル開発)、最終用途別、地域別、セグメント別予測、2024年~2030年


In Vitro Lung Model Market Size, Share & Trends Analysis Report By Type (2D Model, 3D Model), By Application (Physiological Research, 3D Model Development), By End-use, By Region, And Segment Forecasts, 2024 - 2030

体外肺モデル市場の成長と動向 Grand View Research社の最新レポートによると、世界の体外肺モデル市場規模は2030年までに9億4810万米ドルに達し、2024年から2030年までのCAGRは17.4%で成長すると予測されて... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2023年12月4日 US$5,950
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
130 英語

1~3営業日


 

サマリー

体外肺モデル市場の成長と動向

Grand View Research社の最新レポートによると、世界の体外肺モデル市場規模は2030年までに9億4810万米ドルに達し、2024年から2030年までのCAGRは17.4%で成長すると予測されている。市場成長を促進する要因としては、動物実験モデルの代替品作りに重点が置かれるようになっていること、ここ数年の呼吸器関連疾患の世界的な増加などが挙げられる。試験管内肺モデルは、研究者が特定の呼吸器疾患を再現し、潜在的な治療オプションを開発するためにこれらの疾患の細胞および分子特性を密接に模倣するのに役立ちます。このように、疾患のモデル化は試験管内肺モデルの全体的な成長に寄与している。さらに、米国動物愛護協会(HSUS)の報告によれば、米国では毎年約5000万匹の動物が実験に使用されている。動物に対する残酷な行為を軽減するために、動物福祉法(AWA)は動物に対する有害な実験を減らすことを目的とした規制を設けている。

このように、ここ数年、研究分野における動物の倫理的扱いに関する世界的な認識と関心が顕著になってきている。この強調は、試験管内肺モデルに対する世界的な需要の増加に寄与している。さらに、動物を用いた維持や試験には費用がかかるが、in vitroモデルを用いれば、特に化合物や化学物質のハイスループットスクリーニングにおいて、費用対効果が高くなる。この費用対効果の高さは、予算が限られている研究者や組織にとって魅力的であり、試験管内モデルを動物実験に代わる信頼性の高いものにしている。主要参入企業は、世界的な足跡と製品ポートフォリオを拡大するため、パートナーシップ、M&A、契約、製品発表など、さまざまな戦略を採用している。例えば、2023年6月、AlveoliX社は、革新的な3D構造機能を含む新しい臓器オンチップシステムを発表し、あらゆる臓器の模倣をより便利にした。

体外肺モデル市場レポートハイライト

- 利便性、効率性、包括的な性質により、2Dモデルタイプが2023年の市場を独占

- 創薬・毒性試験用途が2023年に市場を席巻、製薬研究開発の初期段階で重要な役割を果たすため

- 最終用途別では、医薬品開発・研究における重要な役割から、製薬・バイオテクノロジー企業が2023年の市場を支配した。

- 北米は、同地域に主要企業や学術研究機関が存在することから、2023年に同産業を支配した。

- 同市場で事業を展開する主要企業は、市場ポジションを維持するため、製品の上市、提携、地理的拡大に絶えず注力している。

ページTOPに戻る


目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Information Analysis
1.2.2. Market Application & Data Visualization
1.2.3. Data Validation & Publishing
1.3. Research Assumptions
1.4. Information Procurement
1.4.1. Primary Research
1.5. Information or Data Analysis
1.6. Market Application & Validation
1.7. Market Model
1.8. Global Market: CAGR Calculation
1.9. Objectives
1.9.1. Objective 1:
1.9.2. Objective 2:
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising prevalence of respiratory diseases
3.2.1.2. Advancement in cell culture technology
3.2.1.3. Increasing number of research activities being done towards pulmonary drug development
3.2.2. Market Restraint Analysis
3.2.2.1. Lack of skilled professional
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
4.1. In Vitro Lung Model Market: Product Movement Analysis
4.2. 2D Model
4.2.1. 2D Model Market, 2018 - 2030 (USD Million)
4.3. 3D Model
4.3.1. 3D Model Market, 2018 - 2030 (USD Million)
Chapter 5. Application Business Analysis
5.1. In Vitro Lung Model Market: Application Movement Analysis
5.2. Drug discovery and Toxicology Studies
5.2.1. Drug discovery and toxicology studies Market, 2018 - 2030 (USD Million)
5.3. Physiological Research
5.3.1. Physiological Research Market, 2018 - 2030 (USD Million)
5.4. 3D Model Development
5.4.1. 3D Model Development Market, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. End-use Business Analysis
6.1. In Vitro Lung Model Market: End-use Movement Analysis
6.2. Academic Research Institutes
6.2.1. Academic Research Institutes Market, 2018 - 2030 (USD Million)
6.3. Pharmaceutical and Biotechnology Companies
6.3.1. Pharmaceutical and Biotechnology Companies Market, 2018 - 2030 (USD Million)
6.4. Others
6.4.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. In Vitro Lung Model Market Share By Region, 2023 & 2030
7.2. North America
7.2.1. North America In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Competitive Scenario
7.2.2.3. Regulatory Framework
7.2.2.4. U.S. In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Competitive Scenario
7.2.3.3. Regulatory Framework
7.2.3.4. Canada In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Regulatory Framework
7.3.2.4. UK In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Regulatory Framework
7.3.3.4. Germany In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. Regulatory Framework
7.3.4.4. France In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Scenario
7.3.5.3. Regulatory Framework
7.3.5.4. Italy In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Scenario
7.3.6.3. Regulatory Framework
7.3.6.4. Spain In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Competitive Scenario
7.3.7.3. Regulatory Framework
7.3.7.4. Denmark In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Competitive Scenario
7.3.8.3. Regulatory Framework
7.3.8.4. Sweden In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Competitive Scenario
7.3.9.3. Regulatory Framework
7.3.9.4. Norway In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. Japan In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. China In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. India In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Regulatory Framework
7.4.5.4. Australia In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Regulatory Framework
7.4.6.4. Thailand In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Regulatory Framework
7.4.7.4. South Korea In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Brazil In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Mexico In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. Argentina In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. MEA In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. South Africa In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. Saudi Arabia In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. UAE In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Kuwait In Vitro Lung Model Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2023
8.4. Company Profiles
8.4.1. Epithelix
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. MATTEK
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. MIMETAS
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Lonza
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Emulate
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. AlveoliX AG
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. InSphero
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. CN Bio Innovations Ltd
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. ATTC Global
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. TissUse GmbH
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives





 

ページTOPに戻る


 

Summary

In Vitro Lung Model Market Growth & Trends

The global in vitro lung model market size is expected to reach USD 948.1 million by 2030, growing at a CAGR of 17.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The factors driving market growth include increasing emphasis on creating substitutes for animal testing models, and recent global rise in respiratory-related disorders over the past few years. In vitro lung models help researchers replicate specific respiratory diseases, closely mimicking the cellular and molecular characteristics of these disorders for the development of potential treatment options. Thus, disease modeling contributes to the overall growth of in vitro lung models. Furthermore, as per The Humane Society of the United States (HSUS) report, about 50 million animals are used in experiments each year in the U.S. To mitigate cruelty to animals, the Animal Welfare Act (AWA) has established regulations aimed at reducing harmful experiments on animals.

Thus, over the past few years, there has been a notable global awareness and concern regarding the ethical treatment of animals in the research field. This emphasis has contributed to the increased demand for in vitro lung models worldwide. Furthermore, maintaining and testing on animals is expensive, whereas the use of in vitro models can be more cost-effective, especially for high-throughput screening of compounds and chemicals. This cost-effectiveness is appealing to researchers and organizations with limited budgets, making in vitro models a dependable alternative to animal testing. Key participants are adopting various strategies including partnerships, mergers & acquisitions, agreements, and product launches, to expand their global footprints and product portfolio. For instance, in June 2023, AlveoliX introduced a new organ-on-chip system that includes innovative 3D structure features, making mimicking any organ more convenient.

In Vitro Lung Model Market Report Highlights

• 2D model type dominated the market in 2023 due to their convenience, efficiency, and comprehensive nature

• The drug discovery & toxicology studies application segment dominated the market in 2023 as these models play a pivotal role in the early stages of pharmaceutical research & development

• Based on end-use, the pharmaceutical & biotechnology companies segment dominated the market in 2023 due to their critical role in drug development & research

• North America dominated the industry in 2023 owing to the presence of key players as well as academic research institutions in the region

• Key players operating in the market constantly focus on product launches, partnerships, and geographical expansions to maintain their market position



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Information Analysis
1.2.2. Market Application & Data Visualization
1.2.3. Data Validation & Publishing
1.3. Research Assumptions
1.4. Information Procurement
1.4.1. Primary Research
1.5. Information or Data Analysis
1.6. Market Application & Validation
1.7. Market Model
1.8. Global Market: CAGR Calculation
1.9. Objectives
1.9.1. Objective 1:
1.9.2. Objective 2:
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising prevalence of respiratory diseases
3.2.1.2. Advancement in cell culture technology
3.2.1.3. Increasing number of research activities being done towards pulmonary drug development
3.2.2. Market Restraint Analysis
3.2.2.1. Lack of skilled professional
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
4.1. In Vitro Lung Model Market: Product Movement Analysis
4.2. 2D Model
4.2.1. 2D Model Market, 2018 - 2030 (USD Million)
4.3. 3D Model
4.3.1. 3D Model Market, 2018 - 2030 (USD Million)
Chapter 5. Application Business Analysis
5.1. In Vitro Lung Model Market: Application Movement Analysis
5.2. Drug discovery and Toxicology Studies
5.2.1. Drug discovery and toxicology studies Market, 2018 - 2030 (USD Million)
5.3. Physiological Research
5.3.1. Physiological Research Market, 2018 - 2030 (USD Million)
5.4. 3D Model Development
5.4.1. 3D Model Development Market, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. End-use Business Analysis
6.1. In Vitro Lung Model Market: End-use Movement Analysis
6.2. Academic Research Institutes
6.2.1. Academic Research Institutes Market, 2018 - 2030 (USD Million)
6.3. Pharmaceutical and Biotechnology Companies
6.3.1. Pharmaceutical and Biotechnology Companies Market, 2018 - 2030 (USD Million)
6.4. Others
6.4.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. In Vitro Lung Model Market Share By Region, 2023 & 2030
7.2. North America
7.2.1. North America In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Competitive Scenario
7.2.2.3. Regulatory Framework
7.2.2.4. U.S. In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Competitive Scenario
7.2.3.3. Regulatory Framework
7.2.3.4. Canada In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Regulatory Framework
7.3.2.4. UK In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Regulatory Framework
7.3.3.4. Germany In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. Regulatory Framework
7.3.4.4. France In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Scenario
7.3.5.3. Regulatory Framework
7.3.5.4. Italy In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Scenario
7.3.6.3. Regulatory Framework
7.3.6.4. Spain In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Competitive Scenario
7.3.7.3. Regulatory Framework
7.3.7.4. Denmark In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Competitive Scenario
7.3.8.3. Regulatory Framework
7.3.8.4. Sweden In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Competitive Scenario
7.3.9.3. Regulatory Framework
7.3.9.4. Norway In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. Japan In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. China In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. India In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Regulatory Framework
7.4.5.4. Australia In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Regulatory Framework
7.4.6.4. Thailand In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Regulatory Framework
7.4.7.4. South Korea In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Brazil In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Mexico In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. Argentina In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. MEA In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. South Africa In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. Saudi Arabia In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. UAE In Vitro Lung Model Market, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Kuwait In Vitro Lung Model Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2023
8.4. Company Profiles
8.4.1. Epithelix
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. MATTEK
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. MIMETAS
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Lonza
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Emulate
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. AlveoliX AG
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. InSphero
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. CN Bio Innovations Ltd
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. ATTC Global
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. TissUse GmbH
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives





 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(バイオ薬物)の最新刊レポート

Grand View Research社の生物分野での最新刊レポート

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/20 10:28

158.95 円

165.20 円

201.28 円

ページTOPに戻る